Articles related to Hematology/Oncology

With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.

Physicians should be acutely aware of the heightened risk of neuroinvasive arboviral infections in patients treated with rituximab, necessitating a shift towards molecular diagnostic testing for timely and accurate detection.

Recent studies have highlighted the effectiveness of ruxolitinib in managing steroid-refractory chronic graft-vs-host disease, showcasing a significant improvement in overall response rates and failure-free survival compared to standard therapies.

In the rapidly evolving field of oncology, artificial intelligence (AI) stands out not just for its potential to revolutionize cancer care, but also for the complex ethical and practical challenges it presents. A recent survey highlights both the enthusiasm and caution among oncologists regarding AI’s integration into clinical practice.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.